Johnson & Johnson (J&J) has expanded its partnership with the US Department for Health and Human Service (HSS)’s Biomedical Advanced Research and Development Authority (BARDA) to commit more than $1bn to co-fund research and development (R&D), as well as clinical testing, of Covid-19 vaccines.
This builds upon an existing partnership between J&J and BARDA to develop anti-viral drugs against the novel coronavirus. This part of the partnership will also receive additional funding; the precise amount was not disclosed.
J&J chairman and CEO Alex Gorsky said: “The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible.
“As the world’s largest healthcare company, we feel a deep responsibility to improve the health of people around the world every day."
Read the full story here.